Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

IMMvention retained rights to use its technology to potentially pursue other targets, such as Parkinson’s or Alzheimer’s ...

IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...

USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license ...

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much ...

Novo Nordisk (NVO) shares traded sharply higher in European trading on Friday after the Danish drugmaker said amycretin, one of its novel obesity therapies, caused up to 22% of weight loss over 36 ...

DURHAM, NC, USA I2, 2025 I IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human ...